Novel crystal form compound of leflunomide and preparation method of novel crystal form compound

A leflunomide and compound technology, applied in the field of pharmaceutical compound preparation, can solve the problem of not giving a spectrum, and achieve the effects of good reproducibility and high purity

Inactive Publication Date: 2019-01-11
SHENZHEN NYCRIST TECH CO LTD
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] Crystal form III is reported in patent CN1411373, which is a solvate of N-methyl-2-pyrrolidone, which is not suitable for drug use. Crystal form IV is reported in patent CN107311954A, with a melting point of 142...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel crystal form compound of leflunomide and preparation method of novel crystal form compound
  • Novel crystal form compound of leflunomide and preparation method of novel crystal form compound
  • Novel crystal form compound of leflunomide and preparation method of novel crystal form compound

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] Example 1: Preparation of Leflunomide Form I (refer to CN107311954A).

Embodiment 2

[0041] Example 2: Preparation of leflunomide crystal form II (refer to CN107311954).

Embodiment 3

[0042] Example 3: Preparation of Leflunomide Form V.

[0043] A preparation method for new crystal form V of leflunomide, comprising the following steps:

[0044] A. Heating leflunomide at a uniform speed until the raw material of leflunomide is completely melted and then vaporized (180-200°C);

[0045] B, cooled to room temperature;

[0046] C. Collect the sample after desublimation of the upper layer of glass.

[0047] Leflunomide Form V has the following characteristics:

[0048] 1. Powder X-ray Diffraction

[0049] Instrument: Sharp Shadow X-ray Diffractometer (PANalytical, Netherlands)

[0050] Target: Cu-Kα radiation

[0051] wavelength:

[0052]X-ray light tube voltage: 45kV

[0053] X-ray tube electric current: 40mA

[0054] Step size: 0.01313°

[0055] Scanning speed: 0.041683° / s

[0056] Scanning range: 2°-40°

[0057] The results show that: at 2θ7.8255°, 8.7099°, 9.1789°, 9.6017°, 11.1488°, 14.9436°, 15.6434°, 18.6293°, 19.3055°, 20.2744°, 23.3166°, 23....

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a crystal form compound of leflunomide V. The crystal form is different from X-ray powder diffraction and differential scanning patterns of the leflunomide, which are publishedin the existing document, and is a novel crystal form; and the X-ray powder diffraction pattern has characteristic diffraction peaks different from a reported crystal form at 2theta of 7.8255 degrees, 8.7099 degrees, 9.1789 degrees, 9.6017 degrees, 11.1488 degrees, 14.9436 degrees, 15.6434 degrees, 18.6293 degrees, 19.3055 degrees, 20.2744 degrees, 23.3166 degrees, 23.5235 degrees, 30.1244 degrees, 30.6877 degrees, 31.5469 degrees and 37.2453 degrees. The solubility of the crystal form is better than that of other all crystal forms in existing reports, the purity is high and the repeatabilityis good; and the invention further discloses a preparation method of the crystal form.

Description

technical field [0001] The invention relates to the field of preparation of pharmaceutical compounds, in particular to a new crystal form compound of leflunomide and a preparation method thereof. Background technique [0002] Leflunomide (Leflunomide), chemical formula: C12H9F3N2O2, molecular weight: 270.2, chemical name: N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide, structural formula I is as follows: [0003] [0004] Leflunomide is an isoxazole immunomodulator with antiproliferative activity, used for the treatment of rheumatoid arthritis, systemic lupus erythematosus, etc., and has been approved in the United States for the treatment of rheumatoid arthritis. [0005] The present invention relates to polymorphs of leflunomide. Polymorphism is the property of certain molecules to assume more than one crystal form in the solid state. Different crystal forms show different weight loss within 110° C. on the X-ray powder diffraction pattern, differential sc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07D261/18
Inventor 田芳安妮·齐默尔曼
Owner SHENZHEN NYCRIST TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap